

Sulforaphane inhibits proliferation by causing cell cycle arrest at the G₂/M phase in rabbit articular chondrocytes

HEE-JEONG JEONG¹, SEON-MI YU¹, JAE-CHANG JUNG² and SONG-JA KIM¹

¹Department of Biological Sciences, College of Natural Sciences, Kongju National University, Gongju 314-701;

²Department of Biology, College of Natural Sciences, Kyungpook National University, Daegu 702-701, Republic of Korea

Received June 11, 2012; Accepted August 20, 2012

DOI: 10.3892/mmr.2012.1057

Abstract. Sulforaphane (SFN), a natural compound extracted from cruciferous vegetables, exhibits potent anticancer activity in various types of tumor cells. However, the effect of SFN on the proliferation of chondrocytes is not well understood. In the present study, we addressed the mechanism of action by which SFN suppresses proliferation. We demonstrate that SFN causes an irreversible arrest in cell proliferation, as determined by trypan blue dye exclusion assay and flow cytometric analysis. SFN induced cell cycle arrest at the G₂/M phase by downregulation of cyclin B, cdc2 and cdc25c and upregulation of p21^{WAF1/CIP1} and p53 in a dose- and time-dependent manner, as determined by western blot analysis. Our data suggest that SFN regulates cell cycle arrest at the G₂/M phase in rabbit articular chondrocytes.

Introduction

Maintenance of articular cartilage integrity and its ability to react to mechanical loads and injury requires a properly orchestrated response of chondrocytes to cellular signals generated by growth factors, the extracellular matrix and cytokines (1). Under physiological conditions, programmed cell death in cartilage is uncommon, owing to maintenance of metabolic homeostasis and chondrocyte adhesion to extracellular matrix proteins (2).

Sulforaphane [SFN; 1-isothiocyanato-4-(methyl-sulfinyl)butane; Fig. 1] is an isothiocyanate identified in broccoli and other cruciferous vegetables. SFN forms following hydrolysis of the glucosinolate compound glucoraphanin by thioglucoside glucohydrolase (3,4). The compound has been revealed to be a naturally occurring cancer chemopreventive agent in animal models (5). Previous studies using animals have demonstrated

the protective effect of SFN with regard to chemically induced carcinogenesis in various organs, including lung, esophagus, liver, mammary gland, colon (6,7) and stomach (8). The chemopreventive activity of SFN has been associated with various effects. However, the mechanism by which SFN exerts its effects on chondrocytes is not fully understood.

SFN has been demonstrated to inhibit neoplastic cell proliferation, block cell cycle progression at G₂/M, cause apoptosis and modulate signal transduction pathways, suggesting that it may be an effective inhibitor of neoplastic cell proliferation and cancer promotion/progression (4,9).

Generally, mammalian cells respond to DNA-damaging agents by activating cell cycle checkpoints, resulting in a delay of cell cycle progression until errors have been corrected (10). Cell cycle arrest at the G₂/M phase prevents cells from completing the cell cycle and proliferating (11). The phase is regulated by the sequential activation and deactivation of cdc family protein and cyclin complexes, including the cdc2/cyclin B complex.

Cyclin-dependent kinases (CDKs), cyclins and CDK inhibitors (CDKIs) are key molecules that play significant roles in cell cycle progression (12). p21^{WAF1/CIP1} is a CDKI protein essential for cellular growth, differentiation and apoptosis (13). Therefore, induction of cell cycle arrest and apoptosis by chemotherapeutic agents is an effective approach to the inhibition of uncontrolled cell proliferation and survival in chondrocytes. We confirm that SFN induces cell cycle arrest at the G₂/M phase via the p21^{WAF1/CIP1} and p53 pathways in rabbit articular chondrocytes. The present study sought to define the signal transduction pathways involved in the disruption of cartilage homeostasis, with the aim of identifying new therapeutic strategies for the prevention of cartilage destruction.

Materials and methods

Cell culture. Rabbit articular chondrocytes were isolated from cartilage slices of 2-week-old New Zealand white rabbits by enzymatic digestion. Cartilage slices were dissociated enzymatically for 6 h in 0.2% collagenase type II (381 U/mg solid; Sigma, St. Louis, MO, USA) in DMEM (Gibco-BRL, Gaithersburg, MD, USA). Individual cells were suspended in DMEM supplemented with 10% (v/v) fetal bovine serum (Gibco-BRL), 50 g/ml streptomycin (USB, Staufen, Germany) and 50 U/ml penicillin (Sigma). Following this, cells were plated on culture dishes at a

Correspondence to: Professor Song-Ja Kim, Department of Biological Sciences, College of Natural Sciences, Kongju National University, Gongju 314-701, Republic of Korea
E-mail: ksj85@kongju.ac.kr

Key words: sulforaphane, proliferation, cell cycle arrest, rabbit articular chondrocytes




Figure 1. Structure of sulforaphane (SFN; molecular weight, 177.29; molecular formula, $C_6H_{11}NOS_2$).

density of 5×10^4 cells/cm². Seeding medium was changed every 2 days, and cells reached confluence in ~5 days. The 3.5-day cell cultures were treated with SFN. SFN was purchased from LKT Laboratories, Inc. (St. Paul, MN, USA). The study was approved by the ethics committee of Kongju National University, Gongju, Republic of Korea.

Western blot analysis. Whole cell lysates were prepared by extracting proteins using a buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40 and 0.1% sodium dodecylsulfate (SDS) supplemented with protease inhibitors (10 g/ml leupeptin, 10 g/ml pepstatin A, 10 g/ml aprotinin and 1 mM AEBSF) and phosphatase inhibitors (1 mM NaF and 1 mM Na_3VO_4). Lysates were size-fractionated by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The nitrocellulose sheet was blocked with 5% non-fat dry milk in Tris-buffered saline. Expression levels of cdc2, cyclin B, cdc25c, p53, p21 and β -actin were detected using antibodies purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Blots were developed using a peroxidase-conjugated secondary antibody and imaged using an ImageQuant LAS 4000 system (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA). Quantification of protein expression was performed using densitometric analysis (Image J).

Cell cycle distribution by FACS analysis. Cell cycle distribution was assessed by staining DNA content with propidium

iodide. Briefly, chondrocytes were plated at a density of 2×10^4 cells/cm² and incubated for 24 h. Fresh media containing SFN were applied to culture dishes and further incubated for 24 h. Following incubation, cells were harvested and fixed with 70% ethanol in PBS overnight. Fixed cells were incubated with RNase A (50 μ g/ml) for 25 min, prior to staining nucleic acid with propidium iodide (50 μ g/ml) for 5 min. The DNA content of 5×10^4 cells/group was analyzed by flow cytometry (Partec GmbH, Münster, Germany) and the results presented as histograms of DNA content. Quantification of the distinct cell cycle phases was calculated using FloMax analysis software (Partec GmbH).

Trypan blue dye exclusion assay. The effect of SFN on the survival/proliferation of rabbit articular chondrocytes was determined by trypan blue dye exclusion assay. Cells were collected by trypsinization, separated into single cell suspensions in culture medium and inoculated into culture dishes at densities of 5×10^4 cells/cm². Following culture for 24 h, cells were exposed to increasing concentrations of SFN or DMSO for 48 h, followed by trypsinization of cells adherent to the culture dishes and cell count analysis by hemocytometer. Each experiment was performed in triplicate. Results were reported as an average of at least three separate experiments.

Data analyses and statistics. Results are expressed as the mean \pm SE, calculated from the specified number of determinations. A Student's t-test was used to compare individual treatments with their respective control value. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

SFN suppresses proliferation of rabbit articular chondrocytes. Phase contrast microscopy (x400; Fig. 2A) demonstrated that treatment of chondrocytes for 24 h with an increasing concentration of SFN, up to 50 μ M, inhibited cell prolifera-




Figure 2. Effect of SFN on cell proliferation. (A) Articular chondrocytes were untreated, or treated with indicated concentrations of SFN for 24 h. Images were captured using a phase contrast microscope (magnification, x200; n=3). (B) Chondrocytes were untreated, or treated with increasing concentrations of SFN for 24 or 48 h. Cell viability was measured using trypan blue exclusion assay. (A and B) Data presented are representative of typical results obtained, and (B) include mean values with standard deviation. * $P < 0.05$, compared with untreated cells (n=4). SFN, sulforaphane.




Figure 3. Effect of SFN on cell cycle distribution. (A and B) Primary articular chondrocytes were untreated, or treated with various concentrations of SFN for 24 h. (C and D) Cells were untreated, or treated with 30 μM SFN for 48 h. (A-D) DNA was stained with propidium iodide and % of cells in phases G₀/G₁ (white), S (gray) and G₂/M (black) were analyzed by flow cytometry. Data presented are representative of typical results obtained (n=3). (D) *P<0.05, compared with untreated cells. SFN, sulforaphane.




Figure 4. Effect of SFN on expression level of cyclin B, cdc2 and cdc25c. (A) Chondrocytes were untreated, or treated with 30 μM SFN for specified time periods. (B) Rabbit chondrocytes were untreated, or treated with the indicated concentrations of SFN for 24 h. (A and B) Expression levels of cyclin B, cdc2, cdc25c and β-actin were determined by western blot analysis. Expression of β-actin was used as loading control. (C) Quantification of the protein contents of cyclin B, cdc2 and cdc25c was performed using densitometric analysis. Data presented are representative of typical results obtained (n=3). *P<0.05, compared with untreated cells. SFN, sulforaphane.




Figure 5. Effect of SFN on expression levels of p53 and p21^{WAF1/CIP1}. (A) Chondrocytes were untreated, or treated with 30 μM SFN for specified time periods. (B) Chondrocytes were untreated, or treated with the indicated concentrations of SFN for 24 h. (A,B) Expression of p53 and p21^{WAF1/CIP1} were determined by western blot analysis. Expression of β-actin was used as loading control. (C) Quantification of the protein contents of p53 and p21^{WAF1/CIP1} by densitometric analysis. Data presented are representative of typical results obtained (n=3). *P<0.05, compared with untreated cells. SFN, sulforaphane.

tion in a dose-dependent manner. Within 48 h, SFN treatment decreased the number of cells attached to the plating surface and the total number of cells present in culture. Treatment with 50 μ M SFN for 24 or 48 h inhibited cell proliferation of chondrocytes by 45 and 38%, respectively (Fig. 2B). These results demonstrate that SFN has a growth inhibitory effect on cell proliferation in rabbit articular chondrocytes (Fig. 2).

SFN causes cell cycle arrest at G₂/M phase. Since SFN inhibits cell proliferation of chondrocytes, we investigated the effects of SFN on cell cycle distribution by flow cytometric analysis. As demonstrated in Fig. 3A, FACS analysis revealed that exposure to SFN for 24 h increased the population of G₂/M phase cells in a dose-dependent manner. Chondrocytes at the G₂/M phase increased from 12.03% (medium alone) to 36.82%, by treatment with 50 μ M SFN (Fig. 3A and B). Exposure of chondrocytes to a growth suppressive concentration of 30 μ M SFN for 48 h resulted in accumulation of cells in the G₂/M phase, and was accompanied by a decrease in cells in the G₀/G₁ phase (Fig. 3C and D). Compared with the control, the percentage of cells in G₂/M phase was increased by ~4-fold, upon treatment with 30 μ M SFN for 48 h (Fig. 3C and D). These results suggest that SFN is effective in suppressing chondrocyte proliferation through induction of cell cycle arrest at the G₂/M phase (Fig. 3). Inhibition of growth was not accompanied by an increase of apoptosis at the G₀/G₁ phase, as determined by FACS analysis (Fig. 3).

SFN inhibits expression of cyclin B1/cdc2 and cdc25c. To determine the molecular mechanisms by which SFN induces G₂/M phase arrest, we examined cell cycle-regulatory proteins involved in the G₂/M phase. Western blot analysis was performed, using antibodies against cell cycle-related proteins (cyclin B1, cdc2 and cdc25c; Fig. 4). SFN treatment resulted in substantial reductions in levels of cyclin B1, cdc2 and cdc25c proteins (Fig. 4A and B). Levels of cyclin 1 and cdc2 decreased faster than levels of cdc25c (Fig. 4A). Quantification of protein content identified a significant reduction of cyclin B1, cdc2 and cdc25c in a dose- and time-dependent manner (Fig. 4C). Collectively, these data indicate that treatment of articular chondrocyte cells with SFN induces expression changes in cell cycle regulators, resulting in subsequent G₂/M phase arrest.

SFN increases p21^{WAF1/CIP1} expression through a p53-dependent pathway. SFN inhibited cell proliferation and induced G₂/M phase cell cycle arrest, observable by flow cytometry analysis. Following DNA damage, p53 activates p21^{WAF1/CIP1} and causes G₂/M phase cell cycle arrest. Expression of p21^{WAF1/CIP1} and p53 in articular chondrocytes exposed to SFN, was examined by western blot analysis. SFN increased expression of p21^{WAF1/CIP1} and p53 in a dose- and time-independent manner (Fig. 5). These data indicate that SFN-mediated G₂/M phase arrest is regulated by the p53/p21^{WAF1/CIP1}-dependent pathway.

Discussion

Cruciferous or brassica vegetables come from the brassica genus and include broccoli, brussel sprout and cauliflower. These vegetables are a good source of glucosinolates, and their

hydrolysis products include indoles and isothiocyanates. SFN is an isothiocyanate associated with chemopreventive activity, linked to inhibition of cell growth and disruption of microtubule polymerization (4). In the present study, SFN inhibited the growth of articular chondrocytes, as determined by trypan blue exclusion assay (Fig. 2B).

Various checkpoint mechanisms function to regulate the cell cycle, ensuring appropriate cellular response to external stresses, including abnormal mitogenic signaling (14).

In an effort to elucidate the mechanism by which SFN treatment results in the inhibition of cell growth, its effects on cell cycle progression were assessed. The present study demonstrated that SFN induces a 27% decrease of G₀/G₁ phase and a 24% increase of G₂/M phase, following 24 h treatment with 50 μ M SFN (Fig. 3A and B). Several studies on SFN have reported that SFN induces cell cycle arrest at the G₂/M phase in cancer cells (15-17). To the best of our knowledge, activation of cdc2, triggered by a positive feedback loop at the end of the G₂ phase, is the key event that initiates mitotic entry (18,19). The present study revealed that SFN treatment, resulting in G₂/M cell cycle arrest in articular chondrocytes, was correlated with decreased levels of cyclin B1/cdc2 and cdc25c (Fig. 4).

Cell cycle progression is mediated by various CDKs whose activities are regulated by CDKIs, including p21^{WAF1/CIP1}. The tumor suppressor gene p53 also regulates inhibition of cell growth (20), and expression of p53 has been revealed to cause a limited arrest in the G₁ phase (21). However, other studies have demonstrated that p53 leads to G₂/M phase progression in the rat cell line REF52, and a human ovarian cancer cell line (22,23). p53 directly stimulates expression of p21^{WAF1/CIP1} to promote cell cycle inhibition. p21^{WAF1/CIP1} competently blocks instigation of early mitotic progression by inhibiting activation of cyclin B and cdc2 (24). The present study suggests that activation of p21 and p53 with SFN may regulate G₂/M phase arrest, by inhibiting formation of cdc2/cyclin B complexes (Figs. 4 and 5). Cdc25c is a major phosphatase which activates cdc2 by dephosphorylation, enabling formation of the cdc2/cyclin B complex. These formations result in mitotic transition of cells (25).

In conclusion, our results demonstrate that SFN inhibits cell growth and induces cell cycle arrest in rabbit articular chondrocytes.

Acknowledgements

This study was supported by the National Research Foundation of Korea funded by the Korea Government (MEST; 2011-00027473 and 2012-0004359).

References

1. Loeser RF, Chubinskaya S, Pacione C and Im HJ: Basic fibroblast growth factor inhibits the anabolic activity of insulin-like growth factor 1 and osteogenic protein 1 in adult human articular chondrocytes. *Arthritis Rheum* 52: 3910-3917, 2005.
2. Pulai JJ, Del Carlo M Jr and Loeser RF: The alpha5beta1 integrin provides matrix survival signals for normal and osteoarthritic human articular chondrocytes in vitro. *Arthritis Rheum* 46: 1528-1535, 2002.
3. Gamet-Payrastra L, Lumeau S, Gasc N, Cassar G, Rollin P and Tulliez J: Selective cytostatic and cytotoxic effects of glucosinolates hydrolysis products on human colon cancer cells in vitro. *Anticancer Drugs* 9: 141-148, 1998.

4. Jackson SJ and Singletary KW: Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. *Carcinogenesis* 25: 219-227, 2004.
5. Parnaud G, Li P, Cassar G, *et al*: Mechanism of sulforaphane-induced cell cycle arrest and apoptosis in human colon cancer cells. *Nutr Cancer* 48: 198-206, 2004.
6. Chung FL, Conaway CC, Rao CV and Reddy BS: Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. *Carcinogenesis* 21: 2287-2291, 2000.
7. Kassie F, Uhl M, Rabot S, *et al*: Chemoprevention of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)-induced colonic and hepatic preneoplastic lesions in the F344 rat by cruciferous vegetables administered simultaneously with the carcinogen. *Carcinogenesis* 24: 255-261, 2003.
8. Fahey JW, Haristoy X, Dolan PM, *et al*: Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of *Helicobacter pylori* and prevents benzo[a]pyrene-induced stomach tumors. *Proc Natl Acad Sci USA* 99: 7610-7615, 2002.
9. Gamet-Payrastré L, Li P, Lumeau S, *et al*: Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. *Cancer Res* 60: 1426-1433, 2000.
10. Zhang C, Zhu H, Yang X, *et al*: P53 and p38 MAPK pathways are involved in MONCPT-induced cell cycle G2/M arrest in human non-small cell lung cancer A549. *J Cancer Res Clin Oncol* 136: 437-445, 2010.
11. Chen AC and Donovan SM: Genistein at a concentration present in soy infant formula inhibits Caco-2BBE cell proliferation by causing G2/M cell cycle arrest. *J Nutr* 134: 1303-1308, 2004.
12. Schwartz GK and Shah MA: Targeting the cell cycle: a new approach to cancer therapy. *J Clin Oncol* 23: 9408-9421, 2005.
13. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. *Nature* 366: 701-704, 1993.
14. Kim JH, Han Kwon K, Jung JY, *et al*: Sulforaphane increases cyclin-dependent kinase inhibitor, p21 protein in human oral carcinoma cells and nude mouse animal model to induce G(2)/M cell cycle arrest. *J Clin Biochem Nutr* 46: 60-67, 2010.
15. Chiao JW, Chung FL, Kancherla R, Ahmed T, Mittelman A and Conaway CC: Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells. *Int J Oncol* 20: 631-636, 2002.
16. Fimognari C, Nüsse M, Cesari R, Iori R, Cantelli-Forti G and Hrelia P: Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. *Carcinogenesis* 23: 581-586, 2002.
17. Herman-Antosiewicz A, Xiao H, Lew KL and Singh SV: Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line. *Mol Cancer Ther* 6: 1673-1681, 2007.
18. Blethrow JD, Glavy JS, Morgan DO and Shokat KM: Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. *Proc Natl Acad Sci USA* 105: 1442-1447, 2008.
19. Chu WF, Wu DM, Liu W, *et al*: Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma. *Oral Oncol* 45: 998-1004, 2009.
20. Ho JW, Song JZ and Leung YK: Activation of p53 by specific agents in potential cancer therapy. *Curr Med Chem Anticancer Agents* 5: 131-135, 2005.
21. Michalovitz D, Halevy O and Oren M: Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. *Cell* 62: 671-680, 1990.
22. Stewart N, Hicks GG, Paraskevas F and Mowat M: Evidence for a second cell cycle block at G2/M by p53. *Oncogene* 10: 109-115, 1995.
23. Vikhanskaya F, Erba E, D'Incalci M and Brogginì M: Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. *Nucleic Acids Res* 22: 1012-1017, 1994.
24. Charrier-Savournin FB, Château MT, Gire V, Sedivy J, Piette J and Dulic V: p21-Mediated nuclear retention of cyclin B1-Cdk1 in response to genotoxic stress. *Mol Biol Cell* 15: 3965-3976, 2004.
25. Su C, Deaton RA, Iglewsky MA, Valencia TG and Grant SR: PKN activation via transforming growth factor-beta 1 (TGF-beta 1) receptor signaling delays G2/M phase transition in vascular smooth muscle cells. *Cell Cycle* 6: 739-749, 2007.